27 completed, 3 terminated, 1 active not recruiting, 1 recruiting. 32 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 32 | Completed 27, Terminated 3, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 8 | Completed 5, Active not recruiting 1, Recruiting 1, Terminated 1 |
Follow Dosage Forms: new trials by email Literature Review of Dosage Forms trials Research Report on Dosage Forms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID) Inflammation (I), Inflammation (II), Inflammation (III) - Covid19 Virus Infection | Phase 1 / Phase 2 | Recruiting | All Natural Medicine Clinic, LLC | 100 | 2025-01-01 | 2025-02-19 |
| A Study to Examine Respiratory Combination Vaccines Against Respiratory Syncytial Virus (RSV) and Flu in Older Adults RSVpreF+qIRV, qIRV, RSVpreF - Healthy | Phase 1 | Completed | Pfizer | 508 | 2023-03-09 | 2024-11-22 |
| A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations Encorafenib capsule formulation (CAP), Encorafenib first formulation, Encorafenib second formulation - Healthy | Phase 1 | Completed | Pfizer | 18 | 2022-07-01 | 2024-02-23 |
| Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN Selumetinib granule formulation, Selumetinib capsule formulation - Neurofibromatosis Type 1 | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 36 | 2022-01-21 | 2026-08-13 |
| Clinical Efficiency of Xanthan Hydrogels Containing Local Anesthetics Encapsulated in Nanostructured Lipid Carries Topical anesthetic - Dental Trauma, Local Anesthesia | Phase 1 | Completed | University of Campinas, Brazil | 40 | 2021-06-02 | 2023-06-22 |
| World Health Organization (WHO) , COVID19 Case Series of Post Covid 19 Rhino Orbito Cerebral Mucormycosis in Egypt debridment - Mucormycosis; Rhinocerebral (Etiology), COVID-19 | Phase 1 / Phase 2 | Completed | Nasser Institute For Research and Treatment | 35 | 2021-05-23 | 2024-02-20 |
| A Relative Bioavailability Study of FOR-6219 in Capsule and Tablet Formulations FOR-6219 capsule formulation, FOR-6219 tablet formulation - Relative Bioavailability | Phase 1 | Completed | Forendo Pharma Ltd | 12 | 2020-12-10 | 2021-01-29 |
| Single and Multiple Ascending Dose Study of CORT125329 in Healthy Participants CORT125329 lipid capsule formulation, Placebo, Prednisone - Healthy | Phase 1 | Completed | Corcept Therapeutics | 115 | 2020-10-23 | 2022-02-09 |
| Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants CORT113176 Lipid Capsule Formulation, Placebo matching CORT113176 Lipid Capsule Formulation, Prednisone - Healthy Adults | Phase 1 | Completed | Corcept Therapeutics | 110 | 2020-01-27 | 2022-02-01 |
| A Study to Assess the Relative Bioavailability of 3 Different Formulations Under Fasted and Fed Condition Verinurad ER8 capsule formulation (fasted), Verinurad A-capsule formulation (fasted), Verinurad A-capsule formulation (fed) - Chronic Kidney Disease | Phase 1 | Completed | AstraZeneca | 25 | 2019-07-20 | 2021-03-18 |
| Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection ChAd155-hIi-HBV low dose formulation, ChAd155-hIi-HBV high dose formulation, HBc-HBs/AS01B-4 low dose formulation - Hepatitis B, Chronic | Phase 1 / Phase 2 | Terminated | GlaxoSmithKline | 236 | 2019-03-28 | 2026-02-20 |
| A Study Evaluating the Safety of Cal-1 (LVsh5/C46) Drug Product in HIV-1 Infected Patient With High Risk Lymphoma Cal-1 (LVsh5/C46) drug product - HIV-1 Infection | Phase 1 / Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 2 | 2019-01-15 | 2025-11-20 |
| Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents Doravirine (DOR), Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF), Antiretroviral (ARV) medications - HIV Infections | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 55 | 2018-07-02 | 2023-02-14 |
| A 6-Part Study In Healthy Volunteers To Evaluate Safety, Tolerability and Uptake Of MEDI7219 in the Body When Given as Single and Multiple Doses MEDI7219, Placebo, Formulation without Active Drug - Healthy Volunteers | Phase 1 | Terminated | MedImmune LLC | 186 | 2017-12-04 | 2020-08-31 |
| Oral Bioavailability,and Food Effect Study and Single Ascending Dose PK Study in Healthy Male Volunteers Indoximod base formulation, Indoximod HCL (salt) formulation, Placebo - Healthy | Phase 1 | Completed | NewLink Genetics Corporation | 48 | 2017-11-21 | 2020-05-28 |
| Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma Immediate Release (IR) Formulation, Gastro-Retentive (GR) Formulation, Dexamethasone - Relapsed or Refractory Multiple Myeloma | Phase 1 | Completed | Amgen | 61 | 2017-01-17 | 2024-09-26 |
| A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects AZD7594 Solution for infusion (150 μg intravenous formulation), AZD7594 Oral suspension (1200 μg oral formulation), AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler) - Asthma, Chronic Obstructive Pulmonary Disease (COPD) | Phase 1 | Completed | AstraZeneca | 30 | 2016-01-12 | 2017-06-15 |
| A Study of LY3039478 in Healthy Participants Placebo, LY3039478 Capsule Formulation (Formulation 3), LY3039478 Drug-in Capsule (Reference, Formulation 1) - Healthy | Phase 1 | Completed | Eli Lilly and Company | 29 | 2016-01-01 | 2025-08-12 |
| A Study To Evaluate The Effect Of Food On The Behavior Of Tofacitinib Modified Release 11 Milligram Tablets In Healthy Western And Japanese Volunteers tofacitinib modified-release (MR) formulation - Healthy | Phase 1 | Completed | Pfizer | 24 | 2014-04-11 | 2018-11-30 |
| Study to Evaluate the PK, Relative Bioavailability and Safety of TG-2349 With Single Oral Dose Under Fed Condition in Healthy Volunteers TG-2349 as the original formulation, TG-2349 as a new capsule formulation - Healthy | Phase 1 | Completed | TaiGen Biotechnology Co., Ltd. | 24 | 2014-04-01 | 2014-12-19 |
Showing 20 of 32. Sign in to see all of them.
COVID-19 (2) · Asthma (1) · Bipolar Disorder (1) · Coronary Restenosis (1) · Cough (1) · Depressive Disorder (1) · Endometriosis (1) · Fever (1) · HIV Infections (1) · Hepatitis B, Chronic (1) · Infections (1) · Inflammation (1) · Influenza, Human (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1)
Pfizer (5) · AstraZeneca (3) · Genzyme, a Sanofi Company (3) · Boehringer Ingelheim (2) · Corcept Therapeutics (2) · University Hospital, Saarland (2) · All Natural Medicine Clinic, LLC (1) · Amgen (1) · Assistance Publique - Hôpitaux de Paris (1) · Eli Lilly and Company (1) · Forendo Pharma Ltd (1) · GlaxoSmithKline (1) · Janssen Research & Development, LLC (1) · MedImmune LLC (1) · Nasser Institute For Research and Treatment (1)
United States (15) · Germany (6) · United Kingdom (5) · Spain (4) · Argentina (2) · Belgium (2) · Brazil (2) · Canada (2) · France (2) · Thailand (2) · Australia (1) · Bulgaria (1) · Egypt (1) · Hong Kong (1) · Italy (1)
Ann Melvin, MD, MPH (1) · Bruno Scheller, MD (1) · Eugene Kennedy, MD (1) · Jens Ricke, MD (1) · Karim Fizazi, MD PhD (1) · Nicole Sims, DO (1)
PMID 18536865, PMID 18779447, PMID 22440499, PMID 28753851, PMID 40370985, PMID 41592259, PMID 42573020
2015 (1), 2017 (1), 2019 (1)